For this week's Tuesday Licensing Forum, on July 18 at 2 p.m. we will have a special presentation and discussion with Kevin E. Noonan, PhD, Partner, McDonnell Boehnen Hulbert & Berghoff LLP.
RNA has been investigated as a vehicle for gene regulation and therapy since the 1980's but is was the success of this approach using mRNA for rapidly producing vaccines against COVID-19 that has accelerated investment and confidence in the method. The webinar will review the scientific background of the technology, examples of its applications, and the economics of bringing therapeutic and prophylactic drugs and vaccines will be discussed.
Tuesday Licensing Forum
Occurs every Tuesday from 2 to 3:30 p.m. ET
Meeting number (access code): 2550 971 1720
Meeting password: P38Ad2DBnQb
About the speaker:
Kevin E. Noonan, PhD, is a partner at McDonnell Boehnen Hulbert & Berghoff LLP in Chicago. Kevin is experienced in all aspects of patenting and in biotechnology and chemistry, representing pharmaceutical and biotechnology companies, as well as universities. He is a founder of the biotechnology and pharma patent law and news weblog, Patent Docs (www.patentdocs.org). In addition to his blog, Kevin writes and lectures extensively on biotechnology patent law. Kevin earned a BS from the State University of New York, a PhD in molecular biology from Princeton University and JD from the John Marshall Law School in Chicago.